Pacific Biosciences of California, Inc.
PACB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $2 | $2 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $1 | $3 | $2 | $5 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -23.2% | 56.3% | -1.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 24.2% | 26.3% | 38.2% | 45.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -157.6% | -135.2% | -220% | -192.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -201.2% | -153% | -244.9% | -138.9% |
| EPS Diluted | -1.07 | -1.21 | -1.4 | -0.89 |
| % Growth | 11.6% | 13.6% | -57.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |